XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.1

Acquisitions, Research Collaborations and License Agreements (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended			3 Months Ended			12 Months Ended
	Apr. 30, 2023	Feb. 28, 2023	Jan. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Research and development					$ 4,276	$ 2,576
Prometheus Biosciences, Inc. | Subsequent Event
Business Acquisition [Line Items]
Asset acquisition, share price (in dollars per share)	$ 200
Asset acquisition, price of acquisition, expected	$ 10,800
Research and development				$ 10,300
Imago Bio Sciences, Inc.
Business Acquisition [Line Items]
Research and development			$ 1,200
Asset acquisition costs			60
Net assets acquired			219
Consideration transferred, asset acquisition			1,350
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Business Acquisition [Line Items]
Research and development		$ 175
Eligible future contingent development-related payments (up to)		1,000
Regulatory milestones payments		2,800
Sales milestone payments		$ 5,500
Preferred stock investment in counterparty			$ 100
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Lenvima
Business Acquisition [Line Items]
Capitalized milestone payment						$ 25	$ 50

X

- Definition

Asset Acquisition, Assets Acquired And Liabilities Assumed, Net

+ References

No definition available.

+ Details

Name:	mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition.

+ References

No definition available.

+ Details

Name:	mrk_AssetAcquisitionSharePrice
Namespace Prefix:	mrk_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Collaborative Arrangement, Preferred Stock Investment In Counterparty

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments

+ References

No definition available.

+ Details

Name:	mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone Payments Made to Collaborative Partner

+ References

No definition available.

+ Details

Name:	mrk_MilestonePaymentsMadetoCollaborativePartner
Namespace Prefix:	mrk_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 55
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of transaction cost incurred as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 30
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 55
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 15
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492

+ Details

Name:	us-gaap_AssetAcquisitionPriceOfAcquisitionExpected
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=mrk_PrometheusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=mrk_EisaiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: